Skip to main content

Table 4 Comparison of incremental values between FGF21/adiponectin ratio and the use of FGF21 or adiponectin alone (n = 4797)

From: FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China

  AUC 95% CI C statistics NRI (%) p value IDI (%) p value C statistics NRI (%) p value IDI (%) p value
Model 1 0.791 0.756–0.826 Ref. Ref. Ref. Ref. Ref.      
 + FGF21/adiponectin ratioa 0.800 0.766–0.833 0.731 27.1 < 0.001 0.7 0.020 Ref. Ref. Ref. Ref. Ref.
 + FGF21a 0.798 0.765–0.832 0.772 17.4 0.021 0.4 0.101 0.955 − 23.5 0.002 − 0.3 0.014
 + Adiponectina 0.793 0.758–0.828 0.939 23.9 0.001 0.3 0.015 0.789 − 18.3 0.016 − 0.3 0.161
Model 2 0.744 0.708–0.780 Ref. Ref. Ref. Ref. Ref.      
 + FGF21/adiponectin ratioa 0.756 0.720–0.791 0.643 32.7 < 0.001 0.6 0.003 Ref. Ref. Ref. Ref. Ref.
 + FGF21a 0.755 0.720–0.790 0.670 30.6 < 0.001 0.5 0.008 0.967 − 11.9 0.114 − 0.1 0.262
 + Adiponectina 0.746 0.710–0.782 0.924 14.6 0.052 0.1 0.074 0.714 − 31.3 < 0.001 − 0.5 0.007
Model 3 0.818 0.782–0.853 Ref. Ref. Ref. Ref. Ref.      
 + FGF21/adiponectin ratioa 0.821 0.785–0.857 0.894 26.9 < 0.001 0.6 0.050 Ref. Ref. Ref. Ref. Ref.
 + FGF21a 0.821 0.785–0.856 0.897 19.8 0.009 0.4 0.083 0.997 − 14.7 0.051 − 0.1 0.212
 + Adiponectina 0.818 0.782–0.853 0.999 18.9 0.012 0.2 0.088 0.896 − 19.8 0.008 − 0.4 0.100
  1. Model 1 included baseline age, BMI, waist circumference, SBP, triglyceride, HDL-C, LDL-C, hsCRP, sex, HOMA-IR, FPG
  2. Model 2 included baseline age, BMI, waist circumference, SBP, triglyceride, HDL-C, LDL-C, hsCRP, sex, HOMA-IR, 2hPG
  3. Model 3 included baseline age, BMI, waist circumference, SBP, triglyceride, HDL-C, LDL-C, hsCRP, sex, HOMA-IR, HbA1c
  4. Values above zero for the NRI and IDI indicate improved risk prediction and discrimination with the addition of biomarkers to the model
  5. 2hPG: 2-h plasma glucose; BMI: body mass index; FGF21: fibroblast growth factor 21; FPG: fasting plasma glucose; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment of insulin resistance; hsCRP: high-sensitivity C-reactive protein; IDI: integrated discrimination improvement; LDL-C: low-density lipoprotein cholesterol; NRI: net reclassification improvement; Ref.: referent; SBP: systolic blood pressure
  6. aLoge-transformed before analysis